 |
|
Cerebrospinal Fluid Levels of  -Secretase—Cleaved Soluble Amyloid Precursor Protein Mirror Cognition in a Swedish Family With Alzheimer Disease and a Gene Mutation
Ove Almkvist, PhD;
Hans Basun, MD;
Steven L. Wagner, PhD;
Blake A. Rowe;
Lars-Olof Wahlund, MD;
Lars Lannfelt, MD
Arch Neurol. 1997;54(5):641-644.
Abstract
| |
Objective
To explore the relationship between possible biological markers of Alzheimer disease that are related to amyloid metabolism and mental functions.
Participants
Twelve individuals from a Swedish family with Alzheimer disease and a double mutation at codons 670/671 of the amyloid precursor protein gene participated in the study.
Design
Cerebrospinal fluid levels of  -secretase cleaved soluble amyloid precursor protein (-sAPP), total sAPP, and amyloid β-peptide were correlated with data on multiple cognitive functions that covered the whole range of human performance.
Setting
The Alzheimer's Disease Research Centre, Department of Clinical Neuroscience, Section of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.
Results
There were highly significant linear correlations between low levels of -sAPP and poor performance on neuropsychological tests that assessed intelligence, verbal and visuospatial functions, memory, and attention. Within the group of nonmutation carriers, significant correlations were also obtained between the levels of -sAPP and cognitive functions. A less striking association was seen between the levels of total sAPP and cognition. No association was found between the levels of amyloid β-peptide and cognition.
Conclusions
The strong relationship between -sAPP levels and cognition in both patients with Alzheimer disease and normal-aging persons may imply that -sAPP is involved in basic protective brain processes. Alternatively, less amyloid β-peptide amounts are produced, leading to diminished plaque formation, when -sAPP is generated.
Author Affiliations
From the Departments of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden (Drs Almkvist, Basun, Wahlund, and Lannfelt), and SIBIA Neurosciences Inc, La Jolla, Calif (Dr Wagner and Mr Rowe).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Reduction of SorLA/LR11, a Sorting Protein Limiting {beta}-Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid
Ma et al.
Arch Neurol 2009;66:448-457.
ABSTRACT
| FULL TEXT
CSF APPs{alpha} and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimer's Type
Fellgiebel et al.
J Geriatr Psychiatry Neurol 2009;22:3-9.
ABSTRACT
The Secreted {beta}-Amyloid Precursor Protein Ectodomain APPs{alpha} Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice
Ring et al.
J. Neurosci. 2007;27:7817-7826.
ABSTRACT
| FULL TEXT
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini et al.
FASEB J. 1998;12:17-34.
ABSTRACT
| FULL TEXT
|
